O	0	6	Effect
O	7	9	Of
B-intervention	10	22	Preoperative
I-intervention	23	34	Intravenous
I-intervention	35	43	Steroids
O	44	46	On
B-condition	47	53	Seroma
I-condition	54	63	Formation
O	64	69	After
O	70	78	Modified
O	79	86	Radical
O	87	97	Mastectomy
O	97	98	.

O	99	103	With
O	104	107	the
O	108	113	steep
O	114	122	increase
O	123	125	in
O	126	132	breast
O	133	139	cancer
O	140	149	incidence
O	150	158	globally
O	159	162	and
O	163	173	regionally
O	173	174	,
O	175	180	there
O	181	184	has
O	185	189	been
O	190	191	a
O	192	197	trend
O	198	204	toward
O	205	213	reducing
O	214	221	patient
O	222	231	morbidity
O	232	234	by
O	235	245	meticulous
O	246	254	surgical
O	255	265	techniques
O	266	268	to
O	269	276	obviate
O	277	290	complications
O	291	295	like
O	296	302	seroma
O	303	312	formation
O	312	313	;
O	314	317	use
O	318	320	to
O	321	324	pre
O	324	325	-
O	325	334	operative
O	335	343	steroids
O	344	349	seems
O	350	352	to
O	353	355	be
O	356	366	convenient
O	366	367	,
O	368	372	cost
O	373	382	effective
O	383	386	and
O	387	392	shows
O	393	402	promising
O	403	410	results
O	411	413	in
O	414	420	trials
O	420	421	.

O	422	426	This
O	427	437	randomized
O	438	446	clinical
O	447	452	trial
O	453	456	was
O	457	466	conducted
O	467	469	at
O	470	478	Surgical
O	479	489	Department
O	490	492	of
O	493	499	Khyber
O	500	508	Teaching
O	509	517	Hospital
O	518	526	Peshawar
O	526	527	,
O	528	532	from
O	533	540	January
O	541	545	2012
O	546	548	to
O	549	554	April
O	555	559	2014
O	560	562	on
B-total-participants	563	565	65
O	566	574	patients
O	575	583	randomly
O	584	593	allocated
O	594	596	to
O	597	602	Group
O	603	604	A
O	605	608	and
O	609	614	Group
O	615	616	B
O	617	622	using
O	623	630	lottery
O	631	637	method
O	637	638	.

O	639	644	Group
O	645	646	A
O	647	656	underwent
B-control	657	660	MRM
I-control	660	661	+
I-control	661	663	AD
I-control	664	666	in
I-control	667	670	the
I-control	671	683	conventional
I-control	684	690	manner
O	691	696	while
O	697	702	Group
O	703	704	B
O	705	713	received
O	714	715	a
O	716	719	120
O	720	722	mg
O	723	725	of
O	726	735	injection
O	736	746	Depomedrol
O	747	760	intravenously
O	761	762	1
O	763	767	hour
O	768	774	before
O	775	778	the
O	779	786	surgery
O	786	787	.

O	788	791	The
O	792	795	two
O	796	800	were
O	801	809	compared
O	810	812	in
O	813	818	terms
O	819	821	of
B-outcome-Measure	822	827	total
I-outcome-Measure	828	836	drainage
O	836	837	,
B-outcome-Measure	838	842	days
I-outcome-Measure	843	845	of
I-outcome-Measure	846	854	drainage
O	854	855	,
B-outcome-Measure	856	861	wound
I-outcome-Measure	862	875	complications
O	876	879	and
B-outcome-Measure	880	889	incidence
I-outcome-Measure	890	892	of
I-outcome-Measure	893	899	seroma
O	899	900	.

O	901	905	Data
O	906	909	was
O	910	917	entered
O	918	921	and
O	922	930	analysed
O	931	936	using
O	937	948	statistical
O	949	956	program
O	957	961	SPSS
O	961	962	-
O	962	964	21
O	964	965	.

O	966	969	The
O	970	974	mean
O	975	978	age
O	979	981	in
O	982	987	group
O	988	989	A
O	990	993	was
B-age	994	996	34
I-age	996	997	.
I-age	997	998	2
I-age	998	999	±
I-age	999	1001	10
I-age	1001	1002	.
I-age	1002	1003	1
I-age	1004	1009	years
O	1010	1013	and
O	1014	1015	B
O	1016	1019	was
B-age	1020	1022	32
I-age	1022	1023	.
I-age	1023	1024	3
I-age	1024	1025	±
I-age	1025	1026	9
I-age	1026	1027	.
I-age	1027	1028	1
I-age	1029	1034	years
O	1034	1035	.

O	1036	1039	The
B-outcome	1040	1044	mean
I-outcome	1045	1053	drainage
O	1054	1056	in
O	1057	1069	intervention
O	1070	1075	group
O	1076	1079	was
O	1080	1093	significantly
O	1094	1101	reduced
O	1102	1104	as
O	1105	1113	compared
O	1114	1116	to
O	1117	1124	control
O	1125	1130	group
O	1131	1132	(
B-iv-cont-mean	1132	1135	755
I-iv-cont-mean	1135	1136	.
I-iv-cont-mean	1136	1137	4
O	1137	1138	±
B-iv-cont-sd	1138	1142	65ml
O	1143	1145	vs
B-cv-cont-mean	1146	1149	928
I-cv-cont-mean	1149	1150	.
I-cv-cont-mean	1150	1151	3
O	1151	1152	±
B-cv-cont-sd	1152	1155	102
I-cv-cont-sd	1155	1156	.
I-cv-cont-sd	1156	1157	5
O	1157	1158	)
O	1158	1159	.

B-outcome	1160	1165	Total
I-outcome	1166	1174	drainage
I-outcome	1175	1179	days
O	1180	1184	were
O	1185	1192	reduced
O	1193	1194	(
B-iv-cont-mean	1194	1195	6
I-iv-cont-mean	1195	1196	.
I-iv-cont-mean	1196	1197	5
O	1197	1198	±
B-iv-cont-sd	1198	1199	1
I-iv-cont-sd	1199	1200	.
I-iv-cont-sd	1200	1201	6
I-iv-cont-sd	1202	1206	days
O	1207	1209	vs
B-cv-cont-mean	1210	1212	10
I-cv-cont-mean	1212	1213	.
I-cv-cont-mean	1213	1214	2
O	1214	1215	±
B-cv-cont-sd	1215	1216	2
I-cv-cont-sd	1216	1217	.
I-cv-cont-sd	1217	1218	2
I-cv-cont-sd	1219	1223	days
O	1223	1224	)
O	1225	1228	and
B-outcome	1229	1238	incidence
I-outcome	1239	1241	of
I-outcome	1242	1248	seroma
O	1249	1252	was
O	1253	1257	also
O	1258	1265	reduced
O	1266	1267	(
O	1267	1268	A
O	1268	1269	=
B-iv-bin-percent	1269	1271	18
I-iv-bin-percent	1271	1272	.
I-iv-bin-percent	1272	1274	75
I-iv-bin-percent	1274	1275	%
O	1276	1278	vs
O	1279	1280	B
O	1280	1281	=
B-cv-bin-percent	1281	1282	6
I-cv-bin-percent	1282	1283	.
I-cv-bin-percent	1283	1285	06
I-cv-bin-percent	1285	1286	%
O	1286	1287	)
O	1287	1288	.

O	1289	1296	However
O	1296	1297	,
B-iv-bin-abs	1298	1303	three
O	1304	1312	patients
O	1313	1315	in
O	1316	1321	group
O	1322	1323	B
O	1324	1327	had
B-outcome	1328	1333	wound
I-outcome	1334	1343	infection
O	1343	1344	.

O	1345	1351	Seroma
O	1352	1361	formation
O	1362	1364	is
O	1365	1368	the
O	1369	1373	most
O	1374	1380	common
O	1381	1393	complication
O	1394	1396	of
O	1397	1407	Mastectomy
O	1408	1411	and
O	1412	1417	among
O	1418	1421	the
O	1422	1429	methods
O	1430	1434	used
O	1435	1437	to
O	1438	1444	reduce
O	1445	1448	its
O	1449	1458	incidence
O	1458	1459	,
O	1460	1467	steroid
O	1468	1482	administration
O	1483	1488	seems
O	1489	1491	to
O	1492	1494	be
O	1495	1498	the
O	1499	1503	most
O	1504	1508	cost
O	1509	1518	effective
O	1519	1522	and
O	1523	1528	shows
O	1529	1538	promising
O	1539	1546	results
O	1546	1547	.
